New hope for aggressive brain cancer: drug may stall tumor return
NCT ID NCT05326464
First seen Dec 18, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study tests whether the drug tofacitinib can slow tumor growth in people with recurrent glioblastoma, a fast-growing brain cancer. About 17 adults whose cancer has returned after standard treatment will take tofacitinib pills twice daily. The main goal is to see how long the tumor stays under control and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.